Nicox Provides Q3 2022 Financials and Operations

Press release
Nicox Provides Third Quarter 2022 Financial and Business Highlights

  • Top line results or NCX 470 Mont Blanc The third phase glaucoma trial expired A generationOne Early November 2022
  • Q3 2022 US regulationsLyrics by VYZULTA® elevated by 37Q3 2021 Percentage
  • Net income €0.8 million for the third quater 2022; cash or EUR 25.6 September 100,000 March 30, 2022

19 October 2022 – Posted at 7:30am CET
Sophia Antipolis, France

Nix (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Nicox SA and its subsidiaries (“Nicox Group”) with financial and business highlights for the third quarter of 2022 and confirmed the upcoming Introduced NCX 470 Mont Blanc Phase 3 timeline clinical trial milestones.

key coming soon MeterGarnet

  • Mont Blanc Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: Top line results to be announced in early November 2022

third Quarter 2022 Financial Summary

The Nicox Group had cash and cash equivalents of EUR 25.6 million as of September 30, 2022, compared to EUR 42 million as of December 31, 2021 and EUR 31.6 million as of June 30, 2022. October 31, 2023 to November 30, 2023, assuming interest-only period extension on existing Kreos debt1, in both cases based on the separately developed NCX 470.just income2 EUR 0.8 million in the third quarter of 2022 (consisting entirely of net royalties). This compares to net income of EUR 2.4 million in the third quarter of 2021 (including net royalties of EUR 0.7 million and license fees of EUR 1.7 million).

As of September 30, 2022, Nicox Group had financial debt of EUR 20.6 million, of which EUR 18.6 million was in the form of a bond financing agreement signed with Kreos Capital in January 2019 and a credit agreement of EUR 2 million guaranteed by the French government. August 2020 in the context of the COVID-19 pandemic.

third Quarter 2022 Business emphasize

  • The last patient completed their last (3-month) visit in the Mont Blanc Phase 3 clinical trial. NCX 470 0.1% is used to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. A total of 691 patients participated in the trial. NCX 470, Nicox’s lead clinical product candidate, is a novel, potentially best-in-class, nitric oxide (NO) donating prostaglandin analog eye drop. Mont Blanc was a 3-month randomized, international, double-blind, parallel-group trial evaluating the efficacy and safety of NCX 470 eye drops 0.1% versus latanoprost eye drops 0.005%. Latanoprost is the most widely used first-line treatment for open-angle glaucoma or ocular hypertension. The primary efficacy assessment for Mont Blanc was based on mean time-matched IOP reduction from baseline at 8 am and 4 pm at Weeks 2, 6 and 3.
  • five results® (Latanoprost Eye Drops), 0.024% US Prescription3 The third quarter of 2022 saw a 37% increase compared to the same period in 2021. VYZULTA is exclusively licensed to Bausch & Lomb globally, approved and commercialized in 8 of 18 markets, with a launch in Brazil expected in the fourth quarter or this year. VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Figures relating only to Nicox Group’s cash position as at 12/31/20twenty one Audited; all other figures exist This press release has not been audited.

About the Knicks
Nicox SA is an international ophthalmic company developing innovative solutions to help maintain vision and improve eye health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also investigating NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, for lowering intraocular pressure and retinal disease. NCX 4251 is a novel, patented fluticasone propionate nanocrystal ophthalmic suspension for topical ocular application in dry eye, developed by Ocumension Therapeutics in China under an exclusive license agreement with collaborations available elsewhere. Nicox earns income from VYZULTA® For glaucoma, exclusive worldwide license to Bausch & Lomb and ZERVIATE® Allergic conjunctivitis, licensed in multiple territories including Eyevance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd.) in the U.S. and Ocumension Therapeutics in China and most of the Southeast Asian market.

Headquartered in Sophia Antipolis, France, Nicox is listed on Euronext Paris (Segment B: Mid Caps; ticker: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information on Nicox, its products or pipeline, please visit:

analyst report
Bryan, Garnier & Co Dylan Van Haaften Paris, France

Edison Investment Research Pooya Hemami London, UK
HC Wainwright & Co. Yi Chen New York, USA
Kepler Cheuvreux Arsene Guekam Paris, France

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may be incorrect or not up-to-date. Nicox undertakes no obligation to correct or update the information contained in the analyst report.

Gavin Spencer
Executive Vice President, Chief Commercial Officer
& Head of Corporate Development
Phone +33 (0)4 97 24 53 00

Investors and Media
America and Europe
Life Science Consultants LLC
Sandy von der Weide
Phone +41 78 680 05 38

forward-looking statements
The information contained in this document may be modified without notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on the current expectations or beliefs of Nicox SA’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, consultants or agents make no undertaking and do not undertake any obligation to update or revise any forward-looking statement.

Risk factors that could materially affect Nicox’s business are described in Chapter 3.Document d’enregistrement Universel, report financier annuel et report de gestion 2021‘ Submitted to the French Financial Markets Authority (AMF) on 29 April 2022, available on the Nicox website (

Draka 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
Phone +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

1 If the Mont Blanc trial of NCX 470 meets its primary endpoint of noninferiority to latanoprost, Nicox has the option to extend the interest-only period on existing Kreos debt by 6 months.
2 Net income includes income from collaborations less royalties and corresponds to net profit in the consolidated income statement.
3 Bloomberg data compares weeks to July 1stone2022 to September 30, 2022, week period July 9 to October 1, 2021stone2021

Source link